2026/07/22
Dermatology
Auxesis Pharma establishes Dermatology as a new complementary business area based on the company’s ASA.P platform.…
Read moreNews
Stay up to date with the latest from Auxesis Pharma. Here you’ll find news about our research, product development, and company progress.
2026-07-10
Auxesis Pharma strengthens its medical expertise
Professor Folke Sjöberg joins Auxesis Pharma as Medical Advisor and Developer of topical pharmaceuticals.…
Read more
2026-07-03
A Historic Milestone for Auxesis Pharma
The Swedish Medical Products Agency has approved the application for the clinical trial of ASA.P®.…
Read more
2026-06-12
Auxesis Pharma strengthens its Board with three new members
At the Annual General Meeting on June 12, 2026, Roar Adelsten was elected Chairman of the Board, while Anna Tenstam and Lars-Olof Peterson were elected Board Me…
Read more
2026/05/13
Stable ASA.P® formulation confirmed after 12 months
12 months of documented stability strengthens the development of ASA.P®…
Read more
2026/05/12
Application Submitted to the Swedish Medical Products Agency – ASA.P® Approaches Clinical Phase
Auxesis Pharma can today announce that on 11 May 2026 the company submitted its application to the Swedish Medical Products Agency for clinical evaluation of AS…
Read more
2026/05/04
Notice of Annual General Meeting
The shareholders of AUXESIS PHARMA HOLDING AB (publ), company registration number 559195-6486, are hereby invited to attend the Annual General Meeting.…
Read more
2026/04/01
How the approval process for clinical studies works in Sweden
In Sweden, a clinical study requires approval from two independent authorities before it can begin:…
Read more